Zhejiang Huahai Pharmaceutical (600521): The integration of Active Pharmaceutical Ingredient and formulation is a leading player, with its Global layout accelerating.

Investment highlights: The Active Pharmaceutical Ingredient Industry is at the upward phase of its cycle, and under multiple catalysts, long-term growth potential is expected to be unlocked. In 2023, the domestic Active Pharmaceutical Ingredient industry experienced high baselines due to orders related to the pandemic in 2022, as well as downstream formulation manufacturers digesting stock accumulated during the pandemic.

Hua Fu SecuritiesDec 20 07:46

Chinese Drug Regulator Accepts Huahai Pharma Unit's Application for Adalimumab Injection

MT NewswiresDec 16 11:52

Huahai Pharmaceutical's Two Drugs Secures Spot in China's National Drug Procurement Program

MT NewswiresDec 16 11:50

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13 21:24

Zhejiang Huahai Pharmaceutical (600521.SH): Products are expected to be selected for the tenth batch of national pharmaceutical centralized procurement.

On December 13, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national drug centralized procurement organized by the National Joint Procurement Office, and the company products Apsaglerone Tablets and Sitagliptin Metformin Tablets (II) are expected to be selected for this centralized procurement.

Gelonghui FinanceDec 13 15:48

Express News | Zhejiang Huahai Pharmaceutical: The subsidiary's application for上市许可for the pharmaceutical Adalimumab injection has been accepted.

BreakingsDec 13 15:44